Business
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asse
About this update from Johnson & Johnson
[{"type":"image","alt":"MeiraGTx","displaySize":"","headline":null,"caption":"MeiraGTx","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eC4lbfkMlXttl7mRddmcYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgz/https://media.zenfs.com/en/globenewswire.com/60ece5081b9af642a0dc8da28326e24c","width":300,"height":59}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec","length":89,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":298,"olType":false},{"type":"text","content":"LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP.","length":341,"tagName":"p"},{"type":"text","content":"“We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “This is a unique opportunity to gain an asset at this stage in development with data supporting a meaningful benefit in patients with no alternative treatment, many of whom are waiting for this life changing therapy and hoping for expeditious approval.”","length":418,"tagName":"p"},{"type":"text","content":"Dr. Forbes continued, “We are intimately familiar with AAV-RPGR, having collaborated with J&J during the development of the program from Phase 1 onward. Importantly, from a regulatory CMC perspective, as the commercial manufacturer of the product, we have completed PPQ with the CMC datasets for filing with global regulators. We intend to start filing BLA and MAA in the U.S., EU and Japan as soon as possible.”","length":416,"tagName":"p"},{"type":"text","content":"Jason Menzo, CE...